Novartis AG Sponsored ADR (NVS)
Novartis to acquire Avidity Biosciences for about $12B
Novartis has been proactively striking deals this year to address the impending patent cliff for some of its blockbuster drugs, including Entresto for heart failure, Xolair for asthma and Cosentyx for autoimmune diseases.
Novartis Deal Values Avidity Biosciences At $12 Billion
The acquisition would raise the 2024-2029 expected sales compound annual growth rate for Novartis to 6% from 5%, it said.
Novartis to acquire Avidity Biosciences for $12 billion
Swiss drugmaker Novartis on Sunday said it agreed to acquire Avidity Biosciences for $12 billion.
Novartis is in talks to buy U.S. biotech firm Avidity Biosciences for more than $70 a share, Bloomberg News reports
Swiss pharmaceutical giant Novartis is nearing a deal to buy biotechnology company Avidity Biosciences for more than $70 a share, Bloomberg News reported.
Novartis nears $70-plus per share deal to acquire Avidity Biosciences, Bloomberg News reports
Swiss drugmaker Novartis AG is close to acquiring U.S. biotech Avidity Biosciences for over $70 per share, Bloomberg News reported on Sunday, citing a person familiar with the matter.
Gear Up for Novartis (NVS) Q3 Earnings: Wall Street Estimates for Key Metrics
Besides Wall Street's top-and-bottom-line estimates for Novartis (NVS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.
Novartis (NVS) is an Incredible Growth Stock: 3 Reasons Why
Novartis (NVS) could produce exceptional returns because of its solid growth attributes.
Novartis' Pluvicto shown to reduce risk of progression or death by 28% in prostate cancer
Swiss drugmaker Novartis said on Sunday its targeted radiotherapy treatment Pluvicto reduced the risk of progression or death in patients with prostate cancer by 28%.
Novartis' Fabhalta slows progression of rare kidney disease in trial
Novartis said on Thursday its Fabhalta drug was shown to meaningfully slow the progression of a rare type of kidney disease under final results of a late-stage trial.
Akero: Novartis Acquisition Puts Focus On Unprecedented MASH Data With EFX
Akero Therapeutics is being acquired by Novo Nordisk for up to $5.2 billion, driven by strong phase 2b results for EFX in F2/F3 pre-cirrhotic and compensated cirrhosis F4 MASH patients. Akero's EFX showed unprecedented reversal of cirrhosis and significant fibrosis improvement in the HARMONY and SYMMETRY studies, respectively, positioning it as a leader in FGF21 analogs. The acquisition includes $54 per share upfront as cash and a $6 per share CVR contingent on FDA approval for compensated cirrhosis due to MASH patients by 2031.
Here's Why Novartis (NVS) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
3 Reasons Growth Investors Will Love Novartis (NVS)
Novartis (NVS) could produce exceptional returns because of its solid growth attributes.
